Scynexis Drug Patent Portfolio
Scynexis owns 1 orange book drug protected by 5 US patents Given below is the list of Scynexis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11534433 | Antifungal agents with enhanced activity in acidic pH | 10 Jun, 2039 | Active |
| US10174074 | Salts and polymorphs of SCY-078 | 19 Jan, 2035 | Active |
| US10370406 | Salts and polymorphs of SCY-078 | 19 Jan, 2035 | Active |
| US10927142 | Salts and polymorphs of SCY-078 | 19 Jan, 2035 | Active |
| US8188085 | Antifungal agents | 28 Aug, 2030 | Active |
Latest Legal Activities on Scynexis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Scynexis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2024 | US10927142 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8188085 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US8188085 |
| Second letter to regulating agency to determine regulatory review period | 21 Dec, 2023 | US8188085 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Nov, 2023 | US8188085 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Oct, 2023 | US8188085 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Feb, 2023 | US10370406 |
|
Recordation of Patent Grant Mailed
Critical
| 27 Dec, 2022 | US11534433 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 27 Dec, 2022 | US11534433 |
|
Issue Notification Mailed
Critical
| 07 Dec, 2022 | US11534433 |
|
Application Is Considered Ready for Issue
Critical
| 22 Nov, 2022 | US11534433 |
| Dispatch to FDC | 22 Nov, 2022 | US11534433 |
|
Issue Fee Payment Verified
Critical
| 18 Nov, 2022 | US11534433 |
|
Issue Fee Payment Received
Critical
| 18 Nov, 2022 | US11534433 |
| Initial letter Re: PTE Application to regulating agency | 25 Aug, 2022 | US8188085 |
Scynexis Drug Patents' Oppositions Filed in EPO
Scynexis drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 09, 2022, by Synthon Bv. This opposition was filed on patent number EP16703009A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP16703009A | Dec, 2022 | Synthon BV | Granted and Under Opposition |
Scynexis's Family Patents
Scynexis Drug List
Given below is the complete list of Scynexis's drugs and the patents protecting them.
1. Brexafemme
Brexafemme is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11534433 | Antifungal agents with enhanced activity in acidic pH |
10 Jun, 2039
(13 years from now)
| Active |
| US10174074 | Salts and polymorphs of SCY-078 |
19 Jan, 2035
(9 years from now)
| Active |
| US10370406 | Salts and polymorphs of SCY-078 |
19 Jan, 2035
(9 years from now)
| Active |
| US10927142 | Salts and polymorphs of SCY-078 |
19 Jan, 2035
(9 years from now)
| Active |
| US8188085 | Antifungal agents |
28 Aug, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brexafemme's drug page